521 studies found for:    multiple myeloma | Open Studies | multiple myeloma
Show Display Options
RSS Create an RSS feed from your search for:
multiple myeloma | Open Studies | multiple myeloma
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Phase 1 Study Evaluating CB-5083 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: CB-5083;   Drug: Dexamethasone
2 Recruiting Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Conditions: Plasma Cell Dyscrasias;   Monoclonal Gammopathy of Undetermined Significance;   AL Amyloidosis;   Multiple Myeloma
Intervention: Procedure: tissue banking
3 Recruiting Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: Group A=30-60 CrCl (mL/min);   Drug: Group B=CrCL<30 mL/min not on dialysis;   Drug: Group C=CrCL<30 mL/min and on dialysis
4 Recruiting Combination Study of Pomalidomide, Marizomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Refractory Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: marizomib;   Drug: low-dose dexamethasone
5 Recruiting Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Conditions: Cancer;   Hematologic Malignancies;   Multiple Myeloma;   Oncology;   Bone Metastases;   Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab;   Drug: Zoledronic acid
6 Recruiting Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Conditions: Relapse Multiple Myeloma;   Refractory Multiple Myeloma
Intervention: Drug: Carfilzomib
7 Recruiting S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Myeloma
Interventions: Biological: elotuzumab;   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
8 Recruiting Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
Condition: Multiple Myeloma
Intervention:
9 Recruiting A Phase 3 Study Comparing Oral IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma
Interventions: Drug: IXAZOMIB + Lenalidomide + Dexamethasone;   Drug: Placebo + Lenalidomide + Dexamethasone
10 Recruiting Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: desipramine hydrochloride;   Biological: filgrastim;   Other: laboratory biomarker analysis
11 Recruiting Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: Autologous Stem Cell Transplant;   Drug: Fludarabine
12 Recruiting Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: TH-302;   Drug: TH-302 and bortezomib
13 Recruiting Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Multiple Myeloma, Refractory
Interventions: Drug: Pomalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
14 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Conditions: Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Smoldering Multiple Myeloma;   Lymphoblastic Lymphoma
Intervention:
15 Recruiting MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Conditions: Multiple Myeloma;   Kahler Disease;   Plasma-Cell Myeloma;   Myelomatosis
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: MLN9708
16 Recruiting Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03)
Conditions: Multiple Myeloma, Relapsed;   Multiple Myeloma, Refractory to Standard Treatment
Interventions: Radiation: Total Marrow Irradiation;   Drug: Melphalan;   Drug: Filgrastim (G-CSF)
17 Recruiting Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dalteparin;   Drug: lenalidomide;   Drug: dexamethasone;   Other: laboratory biomarker analysis
18 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
19 Recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
20 Recruiting Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)
Conditions: Multiple Myeloma;   End Stage Renal Disease
Interventions: Drug: Cyclophosphamide, anti-thymocyte globulin;   Procedure: Kidney transplant;   Radiation: Thymic irradiation;   Procedure: Bone marrow transplant from a related donor

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years